New hope for ALS patients denied entry to other trials
NCT ID NCT07088159
Summary
This program provides access to the experimental drug SPG302 for adults with ALS who cannot join other clinical trials. It aims to evaluate the safety and potential effectiveness of SPG302 in slowing the progression of ALS. The program is for patients who have tried standard treatments and are still experiencing disease progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS (AMYOTROPHIC LATERAL SCLEROSIS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atlantic Health
AVAILABLESummit, New Jersey, 07901, United States
Contact Email: •••••@•••••
-
Baylor College of Medicine
AVAILABLEHouston, Texas, 77030, United States
Contact Email: •••••@•••••
-
California Pacific Medical Center
AVAILABLESan Francisco, California, 94109, United States
Contact Email: •••••@•••••
-
Cedar-Sinai Medical Center
AVAILABLELos Angeles, California, 90048, United States
Contact Email: •••••@•••••
-
Columbia University Medical Center
AVAILABLENew York, New York, 10032, United States
Contact Email: •••••@•••••
-
Dartmouth-Hitchcock Medical Center
AVAILABLELebanon, New Hampshire, 03756, United States
Contact Email: •••••@•••••
-
Kaiser Permanente Los Angeles
AVAILABLELos Angeles, California, 90027, United States
Contact Email: •••••@•••••
-
Massachusetts General Hospital
AVAILABLEBoston, Massachusetts, 02114, United States
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Mayo Scottsdale
AVAILABLEScottsdale, Arizona, 85259, United States
Contact Email: •••••@•••••
-
Nova Southeastern University
AVAILABLEDavie, Florida, 33314, United States
Contact Email: •••••@•••••
-
Synapticure
AVAILABLEChicago, Illinois, 60640, United States
Contact Email: •••••@•••••
-
Thomas Jefferson University
AVAILABLEPhiladelphia, Pennsylvania, 19107, United States
Contact Email: •••••@•••••
-
University of Alabama Birmingham
AVAILABLEBirmingham, Alabama, 35233, United States
Contact Email: •••••@•••••
-
VCU ALS Research Group
AVAILABLEHenrico, Virginia, 23233, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.